Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

The article describes the HORIZON Phase 2 randomized, double-blind, placebo-controlled study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults with MDD. No efficacy/safety results, enrollment timelines, or interim readouts are provided, so the news reads as a study launch/description rather than a catalyst.

Analysis

The article describes the HORIZON Phase 2 randomized, double-blind, placebo-controlled study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults with MDD. No efficacy/safety results, enrollment timelines, or interim readouts are provided, so the news reads as a study launch/description rather than a catalyst.